Administration Delayed Abortion Pill Restrictions
The administration paused plans to restrict mifepristone access until after the upcoming midterm elections.
Updated on Oct. 2, 2026 in Law
Live Poll
Do you trust political leaders to be transparent about their policy plans before an election?
The Trump administration has deferred actions on restricting abortion pill access, citing concerns over voter sentiment before the November midterms. Officials are currently reviewing the 1873 Comstock Act to potentially prohibit the shipment of these medications.
Why it matters
White House Chief of Staff Susie Wiles reportedly warned that implementing aggressive abortion restrictions could alienate voters ahead of the November elections. The administration aims to balance party policy goals with the political risk of significant electoral losses.
Medication abortion accounts for nearly two-thirds of all abortions performed in the United States. While the 2022 Department of Justice opinion currently allows mailing these drugs, the administration intends to rescind that memo.
The players
Todd Blanche
He serves as the Attorney General and has stated that rules permitting the use of abortion pills are wrong.
Robert F. Kennedy Jr.
He is the Secretary of Health and Human Services and initiated a formal FDA review of mifepristone.
Susie Wiles
She serves as the White House Chief of Staff and cautioned that abortion restrictions could hurt electoral performance.
The details
The Department of Justice has requested that federal courts pause ongoing state lawsuits challenging FDA policies on mifepristone. This procedural maneuver allows the administration to avoid immediate judicial rulings that might trigger controversy before voters head to the polls.
Timeline
The Comstock Act was originally passed in 1873.
A Department of Justice memo regarding the Comstock Act was published in 2022.
Attorney General Todd Blanche participated in a confirmation hearing in July 2026.
Midterm elections are scheduled to occur in November 2026.
Political Context
Opponents argue that using the 1873 Comstock Act to restrict medication access represents an executive overreach that ignores modern medical standards. Advocacy groups and dissenting officials maintain that the law was intended to curb the distribution of obscene materials, not medical supplies.
The current delay maintains existing access to mifepristone, allowing patients to continue utilizing medication abortion as a treatment option. Voters should anticipate potential changes to these regulations or legal access paths once the post-election period begins.
The takeaway
The administration is prioritizing electoral outcomes over immediate regulatory changes regarding reproductive healthcare. This strategy reflects a broader attempt to delay polarizing policy decisions until after the midterm cycle concludes.
What happens next
The administration plans to resume its push for abortion pill restrictions and rescind the 2022 legal memo concerning the Comstock Act following the midterm elections in November 2026.
Further reading
For more background on federal legal shifts, visit the United States Law section.
Source note: This article includes information reported by Common Dreams.
Live Poll
Do you trust political leaders to be transparent about their policy plans before an election?
